SUMMARY OF THE PRODUCT CHARACTERISTICS NAME OF THE VETERINARY MEDICINAL PRODUCT
Bimectin vet. 10 mg/ml, solution for injection
QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s) List of excipients PHARMACEUTICAL FORM
Solution for injection. Clear colourless to slightly yellow coloured solution.
PHARMACOLOGICAL PROPERTIES Pharmacodynamic properties
Ivermectin is a member of the macrocyclic lactone class of endectocides, which can bind selectively to glutamate-gated chloride ion channels that occur in several invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve and muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gamma-aminobutyric acid (GABA). The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels. In addition, the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier in normal conditions.
Pharmacokinetic properties
Maximum plasma concentration in cattle is reached on average in 5,5 days and in pigs in 3,5 days after administration. The mean elimination half-life is 6 days in cattle and 5,5 days in pigs. Ivermectin is distributed to tissues in the following order: liver > fat > kidney > muscle in cattle and fat > liver > kidney > muscle in pigs. The substance is only partially metabolised. Unmetabolised ivermectin and degradation products are excreted to about 98 % in faeces and 2 % in urine.
CLINICAL PARTICULARS Target species Indications for use, specifying the target species
Bimectin vet. Injection is indicated for treatment of the following parasites of cattle, reindeer and pigs: Cattle: Gastro-intestinal roundworms (adult and fourth stage larvae, L4) Ostertagia ostertagi. (including inhibited L4) Ostertagia lyrata Haemonochus placei Trichostrongylus axei Trichostrongylus colubriformis (L4) Cooperia spp. Oesophagostomum radiatum Nematodirus spathiger (adult) Lungworms (adult and fourth stage larvae, L4) Dictyocaulus viviparus. Warbles (larval stages) Hypoderma bovis Hypoderma lineatum. Mange mites Sarcoptes scabiei var. bovis Psoroptes bovis Lice Linognathus vituli Haematopinus eurysternus Reindeer Larval stages of Hypoderma tarandi. Pigs: Gastro-intestinal roundworms (adult and fourth stage larvae, L4) Ascaris suum Hyostrongylus rubidus Oesophagostomum spp. Strongyloides ransomi (adult) Lungworms Metastrongylus spp. (adult)
Mange mites Sarcoptes scabiei var. suis Lice Haematopinus suis Contraindications
Should not be given to animals with known hypersensitivity to ivermectin.
Undesirable effects
Local reaction at the injection site may occur.
Special precaution(s) for use
Avermectins/Melbecycins may not be well tolerated in all non-target species (cases of intolerance with fatal outcome are reported in dogs especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles/tortoises).
Pregnancy and lactation
Bimectin vet. Injection can be administered to beef cows and pigs at any stage of pregnancy or lactation. Bimectin vet. Injection should not be given to lactating cows, or heifers and dry cows within 60 days prior to calving, when the milk is intended for human consumption.
Interaction with other veterinary medicinal products and other forms of interaction Posology and method of administration
Bimectin vet. Injection should be given by subcutaneous injection. Cattle and reindeer: 1 ml of Bimectin vet. Injection per 50 kg bodyweight, corresponding to 0.2 mg ivermectin per kg bodyweight. Pigs: 1 ml of Bimectin vet. Injection per 33 kg bodyweight, corresponding to 0.3 mg ivermectin per kg bodyweight.
Overdose
Severe overdose (4-30 mg/kg) can lead to lethargy, ataxia and tremor.
Special warnings for each target species
Neonatal pigs are sensitive for overdosage of ivermectin, presumably due to a more permeable blood-brain barrier. Piglets < 5 days should not be treated.
Withdrawal period Slaughter: Cattle 35 days, reindeer and pigs 28 days. Lactating cows producing milk for human consumption should not be treated. Dry cows and heifers should not be treated within 60 days prior to calving.
Special precautions to be taken by the person administering the veterinary medicinal product to animals. PHARMACEUTICAL PARTICULARS Incompatibilities (major)
Due to lack of incompatibility studies, this veterinary medicinal drug should not be mixed with other veterinary medicinal drugs.
Shelf life
2 years. After first opening, the product should be used within 28 days.
Special precautions for storage
Keep the container in the outer carton, in order to protect from light.
Nature and contents of container
Vials of polyethylene sealed with bromobutyl stoppers and aluminium overseals in cartons. Packaging sizes:
1 x 50 ml 1 x 250 ml 1 x 6 x 250 ml 1 x 500 ml
Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from such medicinal products
Free ivermectin is very toxic to fish and other water-borne organisms. Residual drug must be handed in to the pharamacy for destruction.
PROHIBITION OF SALE, SUPPLY AND/OR USE NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Bimeda (Cross Vetpharm Group Ltd) Broomhill Road Tallaght Dublin 24 Irland
NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION DATE OF REVISION OF THE TEXT
The Walker Group Leading the way towards the winner's circle at. Tampa Bay on Friday, April 8, 2011 Please remember to always check program numbers. Odds shown are morning line. Race 1 12:25pm - Claiming - 8.5 furlongs on the Dirt. Purse: $9,000 Class Rating: 77 FOR FILLIES AND MARES FOUR YEARS OLD AND UPWARD WHICH HAVE NOT WON TWO RACES SINCE OCTOBER 8. WEIGHT, 122 LBS. NON-WINN
In der Regel führt bei Früherkennung eine Therapie in den ersten 24 Stunden zu einer KaninchenInfo EU deutlichen Besserung des Krankheitsbildes, mindestens jedoch zu einem Stillstand der Progredienz der neurologischen Symptome. Gelegentlich werden in den ersten zwei bis drei Tagen Verschlechterungen des Krankheitsbildes beobachtet. Eine Therapie sollte jedoch dann fortgesetzt werden, wenn